Fundraising FoxLung Therapeutics
Austin, US · Founded 2012 · Texas corporation · 2 known investors
Find your way into Lung Therapeutics
Sign up to see every warm intro you have to Lung Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lung Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JB
James Brian WindsorPresident and CEO
SI
Steven IdellNamed on SEC filing
Board
AF
JW
Joseph WoelkersBoard director
RM
Robert MillsBoard director
Investors · 2
Funding
SEC filings, press & company announcements$87.5M disclosed across 4 of 6 rounds · 2014–2022
- Undisclosed amountSeries BJun 2017Source ↗
▶$10.1MraisedApr 2022 · 213 investors · BiotechnologyRule 506(b)
▶$10.1MraisedApr 2022 · 213 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles GarnerExecutive Officer
- Aaron G.L. FletcherDirector
- William C. FaireyDirector
- Brian WindsorExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $10.1M
- Minimum investment
- $15K
- Finders' fees
- $855.5K
- Placement agents
- Newbridge Securities Corporation
- First sale
- Mar 2022
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$38.7MraisedOct 2019 · 42 investors · PharmaceuticalsRule 506(b)
▶$38.7MraisedOct 2019 · 42 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven IdellDirector
- Aaron FletcherDirector
- R. A. SessionDirector
- James Brian WindsorExecutive Officer, Director
- Robert MillsDirector
- Offering amount
- $38.7M
- Amount sold
- $38.7M
- First sale
- May 2019
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$36.2MraisedMay 2019 · 38 investors · PharmaceuticalsRule 506(b)
▶$36.2MraisedMay 2019 · 38 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Steven IdellDirector
- Aaron FletcherDirector
- Robert MillsDirector
- James Brian WindsorExecutive Officer, Director
- R. A. SessionDirector
- Amount sold
- $36.2M
- First sale
- May 2019
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2018 · PharmaceuticalsRule 506(b)
▶Undisclosed amountofferedJun 2018 · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James Brian WindsorExecutive Officer, Director
- Steven IdellDirector
- Aaron FletcherDirector
- Robert MillsDirector
- Jim MervisDirector
- Incorporated
- Corporation, Texas
- Federal exemptions
- 06b
▶$2.6MraisedSep 2015 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.6MraisedSep 2015 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Aaron FletcherDirector
- Joseph WoelkersDirector
- Steven IdellDirector
- Robert MillsDirector
- James Brian WindsorExecutive Officer, Director
- Offering amount
- $2.6M
- Amount sold
- $2.6M
- First sale
- Sep 2014
- Incorporated
- Corporation, Texas, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Lung Therapeutics's investors?
- Lung Therapeutics's investors include UT Horizon Fund, Bios Partners.
- How much funding has Lung Therapeutics raised?
- Lung Therapeutics has disclosed $87.5M raised across 4 of its 6 known rounds.
- Where is Lung Therapeutics headquartered?
- Lung Therapeutics is headquartered in Austin, US.